Le traitement du cancer de l’œsophage localement évolué continue d’évoluer. La chirurgie a longtemps été considérée comme le seul traitement standard, mais la chimioradiothérapie a pris une place majeure dans la stratégie thérapeutique, soit en situation préopératoire, soit à visée exclusive. Bien que certains patients bénéficient toujours de la ch...
Published in Annals of Surgical Oncology
BackgroundThis study compares neoadjuvant chemoradiotherapy (nCRT) with perioperative chemotherapy (pCT) for patients with resectable esophageal or gastroesophageal junction (GEJ) adenocarcinoma in terms of toxicity, postoperative complications, pathologic response, and survival.MethodsThis study retrospectively analyzed and compared 313 patients w...
The management of GOJ cancers remains controversial and may vary between countries. Evidence-based attitudes and guidelines are not easy to elaborate since most of the trials and studies reported mixed cases of oesophageal (both adenocarcinoma and squamous cell tumours), GOJ and gastric cancers. The aim of this expert discussion and position paper ...
Published in Current Oncology Reports
The optimal management of locoregional esophageal cancer is controversial. Preoperative concomitant chemoradiotherapy (two courses of cisplatin and 5-fluorouracil plus 50 Gy of radiation) may provide benefit in survival and local control compared with surgery alone and is a reasonable alternative to surgery alone in stages IIB, III, and possibly st...
Published in World Journal of Surgery
